Ligelizumab

From WikiMD.org
Jump to navigation Jump to search

Ligelizumab

Ligelizumab (pronounced li-ge-li-zu-mab) is a monoclonal antibody designed for the treatment of chronic spontaneous urticaria (CSU), a type of hives. It is developed by Novartis, a Swiss multinational pharmaceutical company.

Etymology

The name "Ligelizumab" is derived from the International Nonproprietary Names (INN), where "li-" refers to the immune system, "-ge-" denotes the target (IgE), "-li-" indicates the source (human), and "-zumab" is a suffix used for humanized monoclonal antibodies.

Mechanism of Action

Ligelizumab works by binding to the Immunoglobulin E (IgE), a type of antibody that plays a crucial role in the allergic response. By binding to IgE, Ligelizumab prevents it from attaching to cells and triggering an allergic reaction.

Related Terms

  • Monoclonal Antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
  • Chronic Spontaneous Urticaria (CSU): A condition characterized by the development of hives, angioedema, or both for at least six weeks due to unknown causes.
  • Immunoglobulin E (IgE): A type of antibody that is primarily involved in allergic reactions.
  • Novartis: A Swiss multinational pharmaceutical company that is one of the largest pharmaceutical companies in the world.

See Also

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski